[{"id":"0c2b46a3-7293-4bb1-9aed-4cb904481f9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986331","created_at":"2023-08-14T15:09:54.144Z","updated_at":"2024-07-02T16:35:36.281Z","phase":"Phase 3","brief_title":"Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma","source_id_and_acronym":"NCT05986331","lead_sponsor":"Biocad","biomarkers":" PROCR","pipe":"","alterations":" ","tags":["PROCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-21"},{"id":"086e7092-bea9-4bd1-9a97-390893241c94","acronym":"","url":"https://clinicaltrials.gov/study/NCT05739006","created_at":"2023-02-22T15:01:05.465Z","updated_at":"2024-07-02T16:35:41.230Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies","source_id_and_acronym":"NCT05739006","lead_sponsor":"Biocad","biomarkers":" PD-L1 • PROCR","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PROCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-08-02"}]